Anti-Human CD3 Antibody (SP34) from ProteoGenix; catalogue PTX18928; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-Human CD3 Antibody (SP34) is a monoclonal antibody that specifically targets the CD3 protein found on the surface of T cells. This antibody has been extensively studied and has shown promising results as a therapeutic target for various diseases. In this article, we will discuss the structure, activity, and potential applications of Anti-Human CD3 Antibody (SP34).
Anti-Human CD3 Antibody (SP34) is a monoclonal antibody, meaning it is produced by a single clone of cells and has a highly specific binding affinity for its target. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The variable regions of these chains determine the specificity of the antibody for its target, in this case, the CD3 protein.
The main function of Anti-Human CD3 Antibody (SP34) is to bind to the CD3 protein on the surface of T cells. This binding triggers a signaling cascade that activates the T cells, leading to their proliferation and production of cytokines. This activation of T cells is crucial for their role in the immune response against pathogens and cancer cells.
In addition to activating T cells, Anti-Human CD3 Antibody (SP34) can also induce apoptosis (programmed cell death) in certain types of T cells. This makes it a potential treatment for diseases characterized by an overactive immune response, such as autoimmune disorders.
One of the most promising therapeutic applications of Anti-Human CD3 Antibody (SP34) is in the treatment of autoimmune diseases. By selectively targeting and depleting specific subsets of T cells, this antibody can suppress the overactive immune response that causes these diseases. In fact, Anti-Human CD3 Antibody (SP34) has already been approved for the treatment of graft-versus-host disease (GVHD), a serious complication of bone marrow transplantation.
Another potential application of Anti-Human CD3 Antibody (SP34) is in the treatment of certain types of cancer. By activating T cells and enhancing their anti-tumor activity, this antibody can potentially be used as an immunotherapy to target and kill cancer cells. Clinical trials are currently underway to evaluate the efficacy of Anti-Human CD3 Antibody (SP34) in various types of cancer, including leukemia, lymphoma, and solid tumors.
Apart from its therapeutic applications, Anti-Human CD3 Antibody (SP34) is also widely used in research. This antibody is commonly used to study the function of T cells and their role in various diseases. It is also used in in vitro experiments to activate T cells and study their response to different stimuli.
Furthermore, Anti-Human CD3 Antibody (SP34) is used in flow cytometry to identify and quantify T cells in a sample. This technique is crucial in monitoring the immune response and assessing the effectiveness of immunotherapies.
In summary, Anti-Human CD3 Antibody (SP34) is a monoclonal antibody that specifically targets the CD3 protein on the surface of T cells. Its main activity is to activate T cells and induce their proliferation and cytokine production. This antibody has shown promising results as a therapeutic target for autoimmune diseases and cancer, and is also widely used in research to study the function of T cells. With ongoing research and clinical trials, Anti-Human CD3 Antibody (SP34) has the potential to revolutionize the treatment of various diseases and improve patient outcomes.
ProteoGenix catalogue number PTX18928. For research use only.
Target: CD3; Host: XtenCHO; Clonality: Monoclonal Antibody; Reactivity: Anti-Human Monoclonal Antibody, Human; Applications: Flow Cyt, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Anti-Human Monoclonal Antibody | ||||||||
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
CD3E identifies CD3 epsilon subunit of T-cell receptor complex in Homo sapiens (Human). This target record connects NCBI Gene 916, UniProtKB P07766 and related ABMIUM catalogue products.
